title: [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
abstract: Bisphosphonates are now the most widely used drugs for osteoporosis. Three bisphosphonates are available in Japan, i.e. etidronate, alendronate and risedronate. In these bisphosphonates, risedronate as the third-generation bisphosphonate was shown in many RCTs to decrease bone resorption biomarkers and to increase BMD. The relative risk of new vertebral fractures and non-vertebral fractures was reduced by about 50% or more. Risedronate is one of the most effective agents for prevention of osteoporotic fractures. Once-weekly treatment with 17.5 mg risedronate showed equivalent efficacy to once-daily treatment with 2.5 mg risedronate, and was well tolerated with favorable safety profiles compared with once-daily dosage regimen.
authors.affiliation: San-in Rosai Hospital, Department of Orthopedic Surgery.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kishimoto
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019317:Evidence-Based Medicine; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid